Thyroid Cancer Clinical Trials Intelligence
Monthly Update Report for Trials Started in August 2026
Powered by Sophic Starlight
Sophic does not practice medicine nor provide medical advice. The Sophic Starlight Cancer Clinical Trials Intelligence Report is provided for educational and consulting purposes only. This report is not a substitute for professional medical advice, diagnosis, or treatment. Sophic shall not be held responsible for any interpretation, application, or use of this report beyond these purposes.
The Sophic Starlight Cancer Clinical Trials Intelligence Report is intended solely as an educational resource that provides access to publicly available clinical trial data integrated within Sophic’s proprietary knowledgebase and summarized with AI. Reports are provided entirely free of charge, and patients should never be billed or charged for access to this information. Users agree to reference Sophic in any publication, presentation, or publicity that incorporates or relies upon information from Sophic Starlight Cancer Clinical Trials Intelligence Reports.
1: Summary data from new trials identified for Thyroid Cancer.
Overview
Number of Trials: 1
This trial evaluates fractionated doses of 211At-MABG, an alpha-particle radiotherapeutic, in adults with advanced neuroendocrine cancers that are MIBG-avid and refractory to standard treatments.
Common Criteria Across Trials
Common Inclusion
- Adults ≥18 years
- Advanced neuroendocrine cancer refractory to or ineligible for standard therapy
- MIBG-avid disease on imaging
- ECOG ≤2
- Adequate organ function (hematologic, renal, hepatic)
- Life expectancy ≥3 months
Common Exclusion
- Pregnant or breastfeeding women
- Uncontrolled brain metastases
- Recent anticancer therapy within 14 days
- Serious unstable medical/psychological conditions
- Other active malignancy within past 2 years
2: Extracted Trials with New Information
Trials with Special Criteria
Genomic / Biomarker Trials
- NCT07661420 — Requires MIBG-avid tumor uptake on imaging as biomarker for eligibility.
Unique or Unusual Criteria
- NCT07661420 — Uses alpha-particle emitting radiotherapeutic (211At) targeting norepinephrine transporter in adrenergic tissue.
Trials with Emerging Treatments
- NCT07661420 — 211At-MABG in Adults With Advanced Neuroendocrine Cancers
Items: 4 MBq/kg 211At-MABG Fractionated, 2 MBq/kg 211At-MABG Fractionated, 1 MBq/kg 211At-MABG Fractionated
Note: Novel alpha-emitting radiopharmaceutical targeting norepinephrine transporter; no FDA approval status listed, sourced from web search.
3: Individual Trial Overviews
NCT07661420
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Organization/Sponsor: University of Pennsylvania
Example patient: A 55-year-old woman with metastatic medullary thyroid cancer refractory to standard therapy, MIBG-avid on imaging, ECOG 1, and normal organ function, not pregnant and without brain metastases.
Phase N/A
NCT07661420
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Organization/Sponsor: University of Pennsylvania
Example patient: A 55-year-old woman with metastatic medullary thyroid cancer refractory to standard therapy, MIBG-avid on imaging, ECOG 1, and normal organ function, not pregnant and without brain metastases.
Interventions
-
Radiopharmaceutical: 4 MBq/kg of 211At-MABG Fractionated
Summary: Alpha-emitting radiotherapeutic targeting adrenergic tissues via norepinephrine transporter, delivering targeted radiation to MIBG-avid tumors including neuroendocrine and thyroid cancers, given in fractionated doses. Source: Summary of Web Search. -
Radiopharmaceutical: 2 MBq/kg of 211At-MABG Fractionated
Summary: Lower-dose alpha particle radiotherapy targeting adrenergic tissue via norepinephrine transporter, aimed at eradicating tumor cells in thyroid and neuroendocrine cancers, administered weekly. Source: Summary of Web Search. -
Radiopharmaceutical: 1 MBq/kg of 211At-MABG Fractionated
Summary: Lowest tested dose of alpha-emitting 211At-MABG targeting adrenergic tumor tissue, fractionated weekly to balance safety and efficacy in thyroid cancer patients. Source: Summary of Web Search.
Key Inclusion
- Age ≥18 years
- Advanced neuroendocrine cancer refractory to standard therapy
- MIBG-avid disease on imaging
- ECOG performance status ≤2
- Adequate hematologic function
- Adequate renal and hepatic function
- Life expectancy ≥3 months
- Written informed consent provided
Key Exclusion
- Pregnant or breastfeeding women
- Unable to tolerate study procedures
- Unstable medical/psychological condition
- Uncontrolled brain metastasis
- Recent anticancer therapy within 14 days
- Other active malignancy within 2 years